Dash Bio has developed a first-in-industry bioanalysis platform that combines a 24,000-square-foot GLP laboratory, robotics, and a proprietary laboratory operating system to productize assays including ELISA, MSD, qPCR, ddPCR, and LC-MS. The platform emphasizes speed, automation, transparent fixed pricing, and end-to-end digital traceability, returning preclinical sample results in days rather than months. Since launching go-to-market efforts roughly nine months ago, Dash has secured contracts with over 30 customers, including four top-15 global pharmaceutical companies. Financially, the company has raised a total of $47.5 million following its $30 million Series A led by Oak HC/FT. Dash plans to use new funding to scale commercial operations, expand its assay menu and lab capacity, move into new categories, and continue developing its proprietary software. The company was founded by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter (CSO).

Total raised

$48M

Funding rounds

3

Latest round

Series A

Latest activity

Aug 2026